Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Biochemical pharmacology - 15 Sept 2009

Wu Chao, Jiang Xi-Ling, Shen Hong-Wu, Yu Ai-Ming

Abstract excerpt

Harmaline is a beta-carboline alkaloid showing neuroprotective and neurotoxic properties. Our recent studies have revealed an important role for cytochrome P450 2D6 (CYP2D6) in harmaline O-demethylation. This study, therefore, aimed to delineate the effects of CYP2D6 phenotype/genotype on harmali...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Behavior
Share to Cytochrome P-450 CYP2D6
Share to Hepatocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Microsomes, Liver

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 19445902
DOI: 10.1016/j.bcp.2009.05.011
PMCID: PMC2728464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19445902-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.PMID 19445902Read ↗

Potential role of CYP2D6 in the central nervous system.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?Semantic proximity Read ↗

Dasotraline as a selective cytochrome 2B6 inhibitor for reaction phenotyping.Semantic proximity Read ↗

Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.Semantic proximity Read ↗

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity Read ↗

Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.Semantic proximity Read ↗

A physiologically based pharmacokinetic model for CYP2E1 phenotyping via chlorzoxazoneSemantic proximity Read ↗

Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.Semantic proximity Read ↗

Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.Semantic proximity Read ↗

In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone.Semantic proximity Read ↗

CYP2D6 phenotype-specific codeine population pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.